NASDAQ:LMNX - Luminex Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$30.12 -0.27 (-0.89 %)
(As of 06/17/2018 04:00 PM ET)
Previous Close$30.12
Today's Range$30.00 - $30.50
52-Week Range$18.62 - $30.50
Volume420,099 shs
Average Volume423,703 shs
Market Capitalization$1.34 billion
P/E Ratio33.10
Dividend Yield0.80%
Beta0.16

About Luminex (NASDAQ:LMNX)

Luminex logoLuminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism. In addition, it offers MultiCode assays and products comprising HSV 1&2 assays, analyte specific reagents, and other products to detect infectious agents in clinical samples; ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 assays, ARIES FLU A/B and RSV assays, ARIES group B strep assays, ARIES group A strep assays, ARIES bordetella assays, and ARIES C. difficile assays; and VERIGENE test cartridges, as well as operates as an original equipment manufacturer of custom reagents and instrumentation. The company serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is based in Austin, Texas.

Receive LMNX News and Ratings via Email

Sign-up to receive the latest news and ratings for LMNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNASDAQ:LMNX
CUSIP55027E10
Phone512-219-8020

Debt

Debt-to-Equity RatioN/A
Current Ratio6.69
Quick Ratio5.20

Price-To-Earnings

Trailing P/E Ratio33.10
Forward P/E Ratio40.16
P/E Growth2.47

Sales & Book Value

Annual Sales$306.57 million
Price / Sales4.37
Cash Flow$1.4101 per share
Price / Cash21.36
Book Value$9.94 per share
Price / Book3.03

Profitability

EPS (Most Recent Fiscal Year)$0.91
Net Income$29.42 million
Net Margins10.60%
Return on Equity8.07%
Return on Assets7.33%

Miscellaneous

Employees922
Outstanding Shares44,450,000

Luminex (NASDAQ:LMNX) Frequently Asked Questions

What is Luminex's stock symbol?

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

How often does Luminex pay dividends? What is the dividend yield for Luminex?

Luminex announced a quarterly dividend on Friday, May 18th. Stockholders of record on Friday, June 22nd will be paid a dividend of $0.06 per share on Friday, July 13th. This represents a $0.24 annualized dividend and a dividend yield of 0.80%. The ex-dividend date is Thursday, June 21st. View Luminex's Dividend History.

How were Luminex's earnings last quarter?

Luminex Co. (NASDAQ:LMNX) issued its earnings results on Monday, May, 7th. The medical instruments supplier reported $0.30 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.22 by $0.08. The medical instruments supplier earned $82.60 million during the quarter, compared to analyst estimates of $80.52 million. Luminex had a return on equity of 8.07% and a net margin of 10.60%. The firm's revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.28 earnings per share. View Luminex's Earnings History.

When is Luminex's next earnings date?

Luminex is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Luminex.

What price target have analysts set for LMNX?

4 Wall Street analysts have issued 1-year target prices for Luminex's stock. Their predictions range from $21.00 to $26.00. On average, they anticipate Luminex's stock price to reach $23.00 in the next twelve months. View Analyst Ratings for Luminex.

Are investors shorting Luminex?

Luminex saw a decline in short interest during the month of May. As of May 31st, there was short interest totalling 1,741,856 shares, a decline of 44.1% from the May 15th total of 3,113,587 shares. Based on an average daily trading volume, of 522,399 shares, the short-interest ratio is presently 3.3 days. Currently, 4.2% of the company's stock are sold short.

Who are some of Luminex's key competitors?

Who are Luminex's key executives?

Luminex's management team includes the folowing people:
  • Mr. Nachum Shamir, CEO, Pres & Director (Age 64)
  • Mr. Harriss T. Currie, CFO, Sr. VP of Fin. & Treasurer (Age 56)
  • Mr. Richard W. Rew II, Sr. VP, Gen. Counsel & Corp. Sec. (Age 50)
  • Mr. Todd C. Bennett, Sr. VP of Global Sales & Customer Operations (Age 48)
  • Mr. Randall J. Myers, Sr. VP of Global Manufacturing & Quality (Age 56)

Has Luminex been receiving favorable news coverage?

Headlines about LMNX stock have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Luminex earned a coverage optimism score of 0.15 on Accern's scale. They also assigned news coverage about the medical instruments supplier an impact score of 46.46 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are Luminex's major shareholders?

Luminex's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (13.95%), Dimensional Fund Advisors LP (4.39%), Neuberger Berman Group LLC (2.60%), Millennium Management LLC (2.34%), Investment Management of Virginia LLC (2.21%) and Northern Trust Corp (2.15%). Company insiders that own Luminex stock include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II, Harriss T Currie, Kevin M Mcnamara, Nachum Shamir, Robert J Cresci and Todd C Bennett. View Institutional Ownership Trends for Luminex.

Which institutional investors are selling Luminex stock?

LMNX stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Neuberger Berman Group LLC, Alambic Investment Management L.P., Thomson Horstmann & Bryant Inc., Elk Creek Partners LLC, Blair William & Co. IL, American International Group Inc. and BNP Paribas Arbitrage SA. Company insiders that have sold Luminex company stock in the last year include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II, Robert J Cresci and Todd C Bennett. View Insider Buying and Selling for Luminex.

Which institutional investors are buying Luminex stock?

LMNX stock was bought by a variety of institutional investors in the last quarter, including Hancock Holding Co., DAFNA Capital Management LLC, Dimensional Fund Advisors LP, Millennium Management LLC, Tamarack Advisers LP, Federated Investors Inc. PA, BlackRock Inc. and Great Lakes Advisors LLC. Company insiders that have bought Luminex stock in the last two years include Harriss T Currie and Nachum Shamir. View Insider Buying and Selling for Luminex.

How do I buy shares of Luminex?

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Luminex's stock price today?

One share of LMNX stock can currently be purchased for approximately $30.12.

How big of a company is Luminex?

Luminex has a market capitalization of $1.34 billion and generates $306.57 million in revenue each year. The medical instruments supplier earns $29.42 million in net income (profit) each year or $0.91 on an earnings per share basis. Luminex employs 922 workers across the globe.

How can I contact Luminex?

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]


MarketBeat Community Rating for Luminex (LMNX)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  152 (Vote Outperform)
Underperform Votes:  270 (Vote Underperform)
Total Votes:  422
MarketBeat's community ratings are surveys of what our community members think about Luminex and other stocks. Vote "Outperform" if you believe LMNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LMNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.